{
  "docId": "019de075-e1f8-726f-9315-81fdfad7abab",
  "docSlug": "b23275bc2e690ecf91711f5f1c92fd3d",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Spyre Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 37,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 14,
  "notes": "The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e1f8-726f-9315-81fdfad7abab/18",
  "deckHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab",
  "deckJsonHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab.json",
  "deckAnchorHref": "/decks/019de075-e1f8-726f-9315-81fdfad7abab#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ADA rates for Nirsevimab, Palivizumab, and Motavizumab (YTE vs non-YTE).",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df14396b-e862-4ca9-8244-f1b66e5b19a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: 1Entyvio prescribing information; 2Rocca, A, et al. Int J of Mol Sci, 2021; 3Domachowske NEJM 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "969693cb-024b-4c8c-9de2-6f732bce9b12",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.02,
        "y": 0.25
      },
      "kind": "table",
      "text": "Vedolizumab vs Placebo safety metrics including infection, serious infection, adverse reaction, malignancy, infusion, and immunogenicity rates.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f19a6bd6-ca97-46ce-aff3-dd97346035c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 is designed to match vedolizumab's favorable safety profile and low rate of ADAs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53ad7a0c-0174-42ae-a1cd-8175654f6079",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a3bebabf-7697-4829-8d97-5bccd26d76e3",
      "evidence": "The slide presents a table/data: Vedolizumab vs Placebo safety metrics including infection, serious infection, adverse reaction, malignancy, infusion, and immunogenicity rates.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 6,
      "beatId": "68c6fca4-e8f4-4ede-b0dc-880b8c41a146",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents a detailed solution, including SPY001 and SPY002, from pages 6 to 19",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0f2e25ea-e3dc-4c15-9e23-1d88590fd563",
      "evidence": "The solution section presents a clear 'why' for Spyre's approach",
      "position": 1,
      "objective": "Why does Spyre's approach make sense?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}